Human Milk Oligosaccharides for Prevention of Alcohol-Associated Liver Disease

NIH RePORTER · NIH · U01 · $157,750 · view on reporter.nih.gov ↗

Abstract

Project Summary Alcohol associated health problems are a major medical burden in industrialized countries. Alcoholic hepatitis is a distinct acute on chronic disease with significant morbidity and mortality. Patients with alcoholic hepatitis show intestinal dysbiosis and increased intestinal permeability. Recent evidence suggests that alcohol-associated liver disease is a gut dysbiosis driven disease. The mechanism of how the microbiota contributes to alcohol-associated liver disease is largely unknown. Results from our laboratory suggest that alterations in the bacterial microbiome contribute to the development of alcoholic liver disease. We observed significantly greater numbers of cytolysin-positive Enterococcus faecalis (E. faecalis) in fecal samples from patients with alcoholic hepatitis, which exacerbates alcoholic liver disease in preclinical models. How chronic alcohol use results in increased cytolysin-positive E. faecalis in the intestine is not known. This Administrative Supplement application will use Human Milk Oligosaccharides (HMOs) as dietary supplement for prevention of alcohol-associated liver disease. We hypothesize that higher numbers of intestinal E. faecalis in the intestine of patients with alcohol use disorder are facilitated by alcohol-associated changes in the glycocalyx of intestinal epithelial cells. We predict that changes in the intestinal glycocalyx can be compensated by dietary supplementation with HMOs. Through the proposed study we will characterize the role of HMOs as important resistance factor for intestinal E. faecalis colonization. Towards this goal, we will use different HMOs as dietary supplements to reduce intestinal E. faecalis and prevent ethanol-induced liver disease in mice (Specific Aim). Our studies will gain novel insights into the contributions of the intestinal microbiota to alcohol-related liver disease, and will find innovative prevention strategies for these diseases. HMOs are ideal supplements, they are safe with a precedent for FDA generally recognized as safe (GRAS) and available from multiple different supplies at large scale and low costs.

Key facts

NIH application ID
10266673
Project number
3U01AA026939-04S1
Recipient
UNIVERSITY OF CALIFORNIA, SAN DIEGO
Principal Investigator
Derrick E Fouts
Activity code
U01
Funding institute
NIH
Fiscal year
2021
Award amount
$157,750
Award type
3
Project period
2018-09-22 → 2023-06-30